Xenova Forms New Firm MetaXen

15 September 1996

UK emerging pharmaceutical company Xenova is forming a new company, MetaXen, which will be located in California in the USA. The new firm will play a key role in Xenova Preclinical, a new division.

MetaXen's initial objectives are to: expand Xenova's drug lead optimization technologies and apply them to accelerate the conversion of Xenova's drug leads into valuable candidate drugs; establish a structure-based drug design group with capabilities in combinatorial and computational chemistry and crystallography, to complement the existing medicinal chemistry group at Xenova in the UK; establish an in vitro metabolism and drug absorption group to create high-throughput assays, which will help predict in vivo behavior of compounds and complement Xenova's existing in vivo pharmacology activities in the UK; apply genomics, transgenic animal models and bioinformatics to enhance Xenova's target technology for the identification of important new therapeutic targets; and engage in new collaborations with pharmaceutical companies on MetaXen drug leads.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight